


# Identification of effective combination therapies for COVID-19 that may reduce the formation of novel variants

August 8 2022, by Anke Sauter



Antiviral effects of approved anti-SARS-CoV-2 drugs in combination with interferon-β (betaferon) against delta, omicron BA.1, and omicron BA.2 isolates. Betaferon was tested in fixed combinations combination with remdesivir (A), EIDD-1931 (B), or nirmatrelvir (C) in SARS-CoV-2 (MOI 0.01)-infected Caco-2-F03 cells. Values represent mean ± S.D. of three independent experiments. D) Combination indices were calculated at the IC<sub>50</sub>, IC<sub>75</sub>, IC<sub>90</sub>, and

IC<sub>95</sub> levels following the method of Chou and Talalay. E) The weighted average CI value (CI<sub>wt</sub>) was calculated according to the formula:

CI<sub>wt</sub> [CI<sub>50</sub> + 2CI<sub>75</sub> + 3CI<sub>90</sub> + 4CI<sub>95</sub>]/10. A CI<sub>wt</sub>

Citation: Identification of effective combination therapies for COVID-19 that may reduce the formation of novel variants (2022, August 8) retrieved 28 April 2024 from

<https://medicalxpress.com/news/2022-08-identification-effective-combination-therapies-covid-.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.